A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Inclusion Criteria:

- Documented history of COPD greater than or equal to (>/=) 12 months prior to Visit 1

- Post-bronchodilator FEV1/FVC less than (<) 0.70 at Visit 1 or 2

- Post bronchodilator FEV1 <80% predicted at Visit 1 or 2

- Documented history of one or more acute COPD exacerbations requiring treatment with
systemic corticosteroids and/or antibiotics or hospitalization within 12 months prior
to Visit 1

- Current tobacco smoker or former smoker (having stopped smoking for at least 6 months
prior to Visit 1) with a history of smoking >/=10 pack-years (20 cigarettes/day for 10
years)

- On inhaled corticosteroids (ICS) therapy for >/=6 months prior to Visit 1

- On an eligible bronchodilator medication for >/=6 months prior to Visit 1

- Chest X-ray or computed tomography (CT) scan within 6 months prior to Visit 1 or chest
X-ray prior to Visit 2 that confirms absence of clinically significant lung disease
besides COPD

- Demonstrated adherence with background COPD inhaler medication during screening period

- For female participants of childbearing age, use of single or combined contraceptive
methods for the duration of the study

Exclusion Criteria:

- History of severe allergic reaction or anaphylactic reaction to biologic agent or
known hypersensitivity to lebrikizumab injection

- History of clinically significant pulmonary disease other than COPD

- Diagnosis of alpha-1-antitrypsin deficiency

- Lung volume reduction surgery or procedure within 12 months prior to Visit 1

- Supplemental oxygen requirement >2 liters/minute (L/min) at rest or with exertion

- Current diagnosis of asthma

- Participants participating in, or scheduled for, an intensive COPD rehabilitation
program

- Maintenance oral corticosteroid therapy

- Treatment with systemic corticosteroids within 4 weeks prior to Visit 1 or during
screen period

- Unstable ischemic heart disease or other relevant cardiovascular disorders

- Use of an immunomodulatory or immunosuppressive therapy including monoclonal
antibodies (includes anti-interleukin-13 (IL) or anti-IL-4/IL-13 therapy)

- Body weight <40 kg

- Any infection that resulted in hospital admission for >/= 24 hours and/or treatment
with oral, intravenous (IV), or intramuscular (IM) antibiotics within 4 weeks prior to
Visit 1 or during screening

- Upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during
screening

- Active parasitic or Listeria monocytogenes infection within 6 months prior to Visit 1
or during screening

- Received a live attenuated vaccine within 4 weeks prior to Visit 1 or during screening

- Active tuberculosis requiring treatment within 12 months prior to Visit 1

- Human immunodeficiency virus (HIV) or other known immunodeficiency

- Hepatitis or known liver cirrhosis

- Aspartate Aminotransferase (AST), Alanine Aminotransferase (ATL), or total bilirubin
elevation >/=2.0 x upper limit of normal (ULN) during screening

- Clinically significant abnormality on screening electrocardiogram (ECG) or laboratory
tests

- History of alcohol or drug abuse

- Pregnant or lactating